Myocardial and Serum Galectin-3 Expression Dynamics Marks Post-Myocardial Infarction Cardiac Remodelling

Citation for published version (APA):

Document status and date:
Published: 01/07/2017

DOI:
10.1016/j.hlc.2016.11.007

Document Version:
Publisher's PDF, also known as Version of record

Document license:
Taverne

Please check the document version of this publication:
- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

Link to publication

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:
www.umlib.nl/taverne-license

Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.

Download date: 17 Sep. 2023
Myocardial and Serum Galectin-3 Expression Dynamics Marks Post-Myocardial Infarction Cardiac Remodelling

Umesh C. Sharma, MD, PhD a*, Wassim Mosleh, MD a, Milind R. Chaudhari, MD, PhD a, Rujuta Katkar, MD a, Brian Weil, PhD a, Chris Evelo, PhD b, Thomas R. Cimato, MD, PhD a, Saraswati Pokharel, MD, PhD c, W. Matthijs Blanksteijn, PhD d, Gen Suzuki, MD, PhD a

©Corresponding author at: Division of Cardiovascular Medicine, Clinical and Translation Research Center, 875 Ellicott Street, Suite 7030, Buffalo, New York 14203. Tel.: +176.829.2663; fax: +176.854.1840. Email: sharmau@buffalo.edu

14203. Tel.: +176.829.2663; fax: +176.854.1840. Email: sharmau@buffalo.edu
© 2016 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.

Background
Acute myocardial infarction (MI) causes significant changes in cardiac morphology and function. Galectin-3 is a novel and potentially therapeutically important mediator of cardiac remodelling. Myocardial and serum galectin-3 expression dynamics in response to the early cardiovascular outcomes after acute MI are not fully elucidated.

Methods
We first performed a comprehensive longitudinal microarray analyses in mice after acute MI. We then measured the serum levels of galectin-3 in a translational porcine model of coronary microembolism-induced post-ischaemic cardiac remodelling. We validated our pre-clinical studies in humans by measuring serum galectin-3 levels of 52 patients with acute ST-elevation MI (STEMI) and 11 healthy controls. We analysed galectin-3 data in relation to the development of major adverse cardiovascular outcomes (MACO).

Results
Of the 9,753 genes profiled at infarcted and remote myocardium at eight different time points, dynamic myocardial overexpression of galectin-3 mRNA was detected. In a pig model of diffuse myocardial damage and cardiac remodelling, galectin-3 localised to the areas of tissue damage and myocardial fibrosis, with proportionate increase of their serum galectin-3 expression levels. In humans, increased serum galectin-3 level was associated with in-hospital MACO.

Conclusions
In this translational study, we demonstrated that galectin-3 is dynamically overexpressed in response to acute MI-induced cardiac remodelling. Elevated galectin-3 levels are associated with the development of in-hospital MACO.

Keywords
Galectin-3 • Myocardial infarction • Remodelling • Microarrays • Fibrosis
Introduction

Congestive heart failure (HF) leads to high morbidity and mortality [1]. The incidence of HF has increased recently due to better survival resulting from newly developed medical therapies and early revascularisation of acute coronary syndromes [2,3]. Early identification of the culprit mechanisms of cardiac remodelling and HF is a major research focus. Prior studies have reported elevated serum galectin-3 levels in patients with LV dysfunction resulted in poor outcomes after acute MI [4,5,6,7,8,9]. Several other population-based and clinical studies have implicated galectin-3 as a strong predictor of cardiovascular events [7–9].

After an acute MI, the myocardium hosts a complex neurohumoral and matricellular response. An abrupt tissue injury leads to loss of cardiomyocytes and surrounding microvasculature. The tissue necrosis is accompanied by a release of cellular byproducts including phospholipids. The loss of microvasculature also leads to altered local osmotic gradients leading to tissue oedema [10]. The vascular stasis and cellular chemotaxis is activated and an inflammatory response then ensues [11]. Concomitantly, a tissue reparative response is triggered, which leads to fibroblast proliferation and gradual deposition of myocardial matricellular proteins in lieu of the damaged cardiomyocytes [11–13].

Once the acute tissue injury is over, an adaptive remodelling is responsible for the maintenance of myocardial morphology and function [12,14]. The adapting ventricles often tend to dilate, whereas the lost cardiomyocytes are gradually replaced by cardiac fibroblasts and collagen fibres [15]. Overall, this dichotomy of tissue damage and repair ultimately determines the long-term outcomes related to ischaemic cardiomyopathy. A smaller infarct size, early revascularisation and initiation of anti-remodelling therapy can have beneficial effects, whereas the opposite will lead to adverse remodelling and loss of cardiac function leading to HF.

Several studies have examined the post-MI course in small and large translational animal models [14,16–18]. However, given the extended course of myocardial recovery, longitudinal genome-based studies have been difficult to perform on large animal models, and determination of the pathophysiological process of myocardial tissue injury, inflammation and repair has been difficult. Therefore, we have used a preclinical small animal model for the large-scale longitudinal genomics analysis. After the completion of the initial unbiased genomics profiling, we have performed additional hypothesis-driven studies on translational porcine models of MI for the validation of initial data on galectin-3 expression in relation to the development of cardiac dysfunction. Furthermore, in support of our preclinical translational findings, we have also conducted clinical studies to validate the association between elevated serum galectin-3 levels and early development of major adverse cardiovascular outcomes (MACO) in patients with acute ST-elevation myocardial infarction (STEMI).

Methods

Murine Studies

Experimental MI

We induced MI in 24 Swiss mice (age 10–12 weeks) using our study protocol described previously [19]. Briefly, xylazine (5 mg/kg s.c.) and ketamine (1 mg/kg i.m.) anaesthetised and intubated mice underwent a ligation (6-0 prolene) of the left anterior coronary artery. After a successful closure of chest wall with 5-0 silk sutures, mice were allowed to recover at 30 °C. Sham surgeries were performed identically, except for the coronary artery ligation. Upon sacrifice, we isolated tissue RNA using an RNeasy Mini Kit (QIAGEN, Hilden, Germany). The Institutional Animal Care Committee of Maastricht University approved the procedure for care and treatment of animals. All procedures performed in the studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Microarrays

We used the Incyte mouse GEM-2 cDNA libraries with 9,753 reporter genes for a microarray analysis (Incyte Genomics, Palo Alto, CA). Duplicate hybridisations were performed on these glass chips with pooled (N=3, each group) mRNA samples obtained from acute infarct and remote myocardial regions. Since our primary question was to identify the temporal transcriptional profile following acute MI in the preclinical mouse model, we performed a comprehensive genomic profiling using multiple time points. We performed microarray analyses for a total of eight time-points so that a broad and comprehensive gene expression profiling in both infarct and remote myocardial segments could be identified. The early response to acute myocardial injury was examined at four distinct time-points (one day, two days, four days and seven days). The intermediate tissue repair and myocardial adaptive response was examined at two additional time-points (14 days and 21 days). An additional two time-points (45 days and 90 days) were chosen to identify the chronic myocardial gene expression profile in response to post-ischaemic myocardial remodelling. For maximal accuracy, we only included those reporter spots in which at least 40% of pixels displayed fluorescence more than 2.5-times local background. The protocol for data mining and validation was adopted as detailed previously [20,21].

Porcine Studies

Experimental MI

We have previously generated representative porcine models of acute MI [22,23]. The coronary microembolisation model shows multiple, heterogeneous and patchy areas of myocardial scarring, and significant loss of myocardial function. In a study subset designed to examine galectin-3 expression dynamics, we generated acute MI in six Mini-swines.
(weight, 21–33 Kg) by infusing polystyrene microspheres (Polysciences, Inc. PA, USA). The microspheres were injected over five minutes under continuous ECG monitoring, as described previously [24]. Previous studies using this model have also demonstrated severe left ventricular dysfunction immediately following microsphere injection and persisting as long as three months, with patchy areas of infarction that typically amounted up to approximately 20% of LV mass [25]. The Institutional Animal Care Committee of University at Buffalo approved the procedure for care and treatment of animals.

**Two-Dimensional Echocardiography**
We performed 2D transthoracic echocardiography for the evaluation of LV systolic function, as previously described in pigs [26,27]. We obtained digitised images using a GE Vivid 7 sonography machine. The LV was imaged in the short-axis and long-axis projections from a right parasternal approach. Measurements were performed using the recent criteria reported by American Society of Echocardiography [28]. M-mode measurements of wall thickness were obtained to calculate regional functions. End-diastole was defined as the onset of the R wave and end-systole was taken as the minimal chamber dimension during ejection. Ejection fraction was used to assess global LV function.

**Serum Galectin-3 Measurements**
For galectin-3 serum measurements, we used a pre-coated galectin-3 specific 96-well strip microplate ELISA kit (RayBiotech, Norcross, GA). Galectin-3 immunoassays were performed in duplicate wells using pig serum samples obtained three months after the induction of acute MI. In this colourimetric quantitate sandwich ELISA, the measured optical densities were analysed with pre-determined standard galectin-3 concentrations according to the manufacturer’s recommendations.

**Myocardial Galectin-3 Staining**
For myocardial galectin-3 detection, we performed immuno-histochemistry using galectin-3 specific antibody (R&D Systems). The 4 mic formalin-fixed paraffin embedded tissues were incubated with an autostainer in a serum free protein block (Dako). Slides were then incubated for an hour with 1:1000 anti-galectin-3 antibody. Secondary antibody (JIRL) and rabbit envision labelled polymer Horseradish peroxidase anti-rabbit antibody (Dako) were then applied for 30 minutes. We used DAB substrate kit (Dako) for chromogen visualisation before counterstaining the slides with haematoxylin.

**Human Studies**

**Patient Selection**
At Gates Vascular Institute and Buffalo General Medical Center, informed consent was obtained from a total of 52 patients for participation in an observational study. The inclusion criteria consisted of patients who presented with a newly diagnosed ST-elevation myocardial infarction (STEMI) and underwent revascularisation by percutaneous intervention (PCI). Exclusion criteria included patients with documented history of trauma, MI or stroke within the preceding six months, or active malignancies in order to avoid any influences on circulating galectin-3 levels. Eleven healthy volunteers were recruited as controls for baseline galectin-3 levels. The study protocol was approved by the institutional review board of the University at Buffalo.

**Serum Galectin-3 Measurements**
Blood samples were collected within 12 to 48 hours from initial presentation for measurement of circulating galectin-3 levels. After centrifugation, samples were stored in heparinised test-tubes in refrigerators at -80°C until galectin-3 assays were performed. For galectin-3 serum measurements, a pre-coated galectin-3 specific 96-well strip microplate ELISA kit (RayBiotech, Norcross, GA) was used and measured optical densities were analysed with pre-determined standard galectin-3 concentrations according to the manufacturer’s recommendations.

**Clinical Endpoints**
Baseline characteristics and in-hospital outcomes of all the patients were recorded by chart review. Comparisons between galectin-3 levels in study subjects and controls were performed and fold-increase in galectin-3 level from baseline (healthy controls) was calculated. The primary study end-point was the composite outcome of early major adverse cardiovascular outcomes (MACO), which is defined as in-hospital mortality, stroke, recurrent MI, or severely reduced left ventricular ejection fraction (LVEF) of ≤35% on ventriculogram performed at the time of revascularisation. Second-ary endpoints included: (a) Severely reduced left ventricular ejection fraction (LVEF) of ≤35% on ventriculogram; (b) Elevated left ventricular end diastolic pressure (LVEDP) of >20 on ventriculogram; (c) Presence of diastolic dysfunction greater than stage 2 on echocardiogram; (d) Elevated E/E’ ratio ≥15 on echocardiogram; and (e) Atrial volume index ≥35 on echocardiogram.

**Statistical Analysis**
For microarray studies, data are expressed as fold change over control in densitometric units. The microarray study design utilised a pooled tissue (N=3, each time point, infarct and remote zones compared to sham group) to isolate the mRNAs and therefore, a weighted gene pool was presumed to be present during hybridisation. Paired group differences were compared with Student’s T-test for normally distributed data. Mann-Whitney U-test was used to find difference between groups without normal distribution. Kruskal-Wallis test followed by Mann-Whitney U-test with Bonferroni correction was used to compare a) Normal vs LVEF <35%; b) normal vs LVEF >35%; and c) LVEF <35% vs >35%. Differences between categorical variables were analysed using Chi-square test or Fisher exact test as appropriate. Statistical data analysis was performed using SPSS software for Windows, version 23 (SPSS Inc., IL, USA). Differences between the groups were considered to be significant when p <0.05.
Results

Post-MI Dynamic Overexpression of Galectin-3 mRNA in Murine Myocardium Compared to Natriuretic Peptide Precursor (NPP)

The gene expression profile in post-MI groups has been presented as fold-change compared to the mice with Sham surgery. Comparison of galectin-3 expression dynamics with NPP showed early and rapid increase of NPP mRNA expression post-MI. Natriuretic peptide precursor expression peaked at two days, with its expression level reaching to the baseline levels at 90 days. Natriuretic peptide precursor is expressed in the heart in relation to myocardial stretch response. Compared to NPP, galectin-3 showed a relatively delayed overexpression profile with eight-fold overexpression at 14 days and six-fold overexpression at 21 days (Figure 1A). Unlike a robust overexpression of galectin-3 mRNA in the infarct region, minimal galectin-3 overexpression was noted in the remote myocardium (fold increase: 1.1, 1 day; 1.5, 2 days; 1.4, 4 days; 1.1, 7 days; 1.2, 14 days; 1.1, 21 days; 1, 45 days; and 1.3, 90 days), with highest overexpression (1.5-fold) noted two days after acute MI.

Concerted Overexpression of Galectin-3 With Other Genes Related to Cardiac Remodelling in Mice

Cardiac remodelling involves complex and dynamic interactions between cardiomyocytes, fibroblasts, inflammatory cells and matricellular proteins [29,30]. We noted the stream of pathological changes progressing in a concerted pattern during post-ischaemic cardiac remodelling (Table 1). Of the 9,753 unique genes, we identified galectin-3 as a dynamically expressed molecule in linearity with other genes crucial for myocardial remodelling. The most robustly expressed genes including cathepsin S, pro-collagen and macrophage expressed genes are already known to be crucial for the tissue scavenger and reparative response [21,30,31]. This temporal profiling of galectin-3 gene expression showed the majority of genes related to cardiac remodelling to peak at 14 days (Figure 1B), which, in fact, may represent a critical time point to initiate or maximise medical therapy. Also in line with current observations, we have previously shown galectin-3 to be a dynamic mediator of hypertension-induced cardiac remodelling, in which galectin-3 was a likely culprit molecule to induce cardiac fibroblast proliferation, collagen deposition and cardiac dysfunction [4,32].

Increased Serum Galectin-3 Levels in a Porcine Model of Cardiac Dysfunction

The Mini-pigs that underwent a coronary microembolism procedure showed significant cardiac remodelling and loss of cardiac function (Table 2). Compared to other porcine models of coronary ligation, coronary microembolism induces diffuse and patchy myocardial damage and leads to extensive alteration of myocardial morphology and function. In our quantitative enzymes-linked assays, we found a more than five-fold increase of serum galectin-3 levels in the post-coronary embolism model that also showed severely reduced LV systolic function (Figure 2 A and B). Serum galectin-3 was not detected in one sample, but in the remaining samples, analysis of linear trendline generated by the comparison of LV ejection fraction vs. serum galectin-3 showed a correlation co-efficient of 0.9485. These findings are also supportive of our current state of clinical practice in which serum galectin-3

---

**Figure 1** Temporal gene expression profile of five mRNAs (galectin-3, natriuretic peptide precursor, cathepsin S, procollagen and macrophage expressed gene 1) that showed the most robust differential expression in infarct regions. The data columns represent fold-change of mRNA expression and rows represent the 8 time points chosen for genomic profiling after the induction of acute MI. Panel A represents the unique time points that show the peak expression of ANPP (2-days) and Galectin-3 (2-weeks). Panel B shows a concerted Galectin-3 expression profile that follows the expression dynamics of several others inflammatory and reparative genes associated with cardiac remodeling.
increase is associated with worse clinical outcomes, including rapid progression of HF and early mortality [33-35].

**Galectin-3 Co-Localisation to Damaged Myocardium in Pigs**

Immunohistochemistry showed strong galectin-3 positivity in the damaged myocardial segments. Consistent with our prior observations, the galectin-3 positive cells appeared large and vacuolated, which were previously confirmed to be macrophages by CD68 staining and in-situ hybridisation [4] (Figure 3A). These findings are also consistent with our previously reported experiments in which we showed macrophages as the source of galectin-3, whereas cardiac fibroblasts had perinuclear and cytoplasmic galectin-3 receptors [4]. The control hearts showed no evidence of myocardial damage or galectin-3 expression (Figure 3B).

**Increased Serum Galectin-3 Levels After Acute STEMI in Patients With Cardiac Dysfunction and Adverse Outcomes**

The results of pre-clinical study in the porcine model were validated in a clinical study. Demographic characteristics of study patients are illustrated in Table 3. STEMI patients developing MACO (MACO-positive) compared to without

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Temporal Expression Profile of 25 Most Robustly Overexpressed Genes after Acute Myocardial Infarction</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 day</td>
</tr>
<tr>
<td>1. Osteoblast specific factor 2 (fascinl I-like)</td>
<td>2.7</td>
</tr>
<tr>
<td>2. Lysyl oxidase</td>
<td>2.1</td>
</tr>
<tr>
<td>3. Galectin-3</td>
<td>1.8</td>
</tr>
<tr>
<td>4. Stromal cell derived factor 5</td>
<td>3.4</td>
</tr>
<tr>
<td>5. Procollagen, type I, alpha 2</td>
<td>2.1</td>
</tr>
<tr>
<td>6. Procollagen, type I, alpha 1</td>
<td>2.1</td>
</tr>
<tr>
<td>7. Cathepsin S</td>
<td>1.9</td>
</tr>
<tr>
<td>8. Macrophage expressed gene 1</td>
<td>1.6</td>
</tr>
<tr>
<td>9. Microfibrillar associated protein 5</td>
<td>2.2</td>
</tr>
<tr>
<td>10. Natriuretic peptide precursor type A</td>
<td>4.2</td>
</tr>
<tr>
<td>11. Secreted acidic cysteine rich glycoprotein</td>
<td>1.3</td>
</tr>
<tr>
<td>12. Fibulin 5</td>
<td>1.7</td>
</tr>
<tr>
<td>13. Thrombospondin 2</td>
<td>2.1</td>
</tr>
<tr>
<td>14. CD68 antigen</td>
<td>1.4</td>
</tr>
<tr>
<td>15. Latent transforming growth factor beta binding protein 2</td>
<td>2.5</td>
</tr>
<tr>
<td>16. Lysosomal-associated protein transmembrane 5</td>
<td>2</td>
</tr>
<tr>
<td>17. ESTs, Weakly similar to rat cartilage oligometric protein</td>
<td>1.6</td>
</tr>
<tr>
<td>18. Lysyl oxidase-like protein</td>
<td>2.3</td>
</tr>
<tr>
<td>19. ESTs, Highly similar to fibrinogen like protein</td>
<td>2.1</td>
</tr>
<tr>
<td>20. Biglycan</td>
<td>2.3</td>
</tr>
<tr>
<td>21. Procollagen, XIV, alpha 1</td>
<td>2</td>
</tr>
<tr>
<td>22. Apolipoprotein E</td>
<td>2.1</td>
</tr>
<tr>
<td>23. Procollagen, type II, alpha 1</td>
<td>1.8</td>
</tr>
<tr>
<td>24. Pigment epithelium-derived factor</td>
<td>2.1</td>
</tr>
<tr>
<td>25. Fibrillin 1</td>
<td>1.4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Echocardiographic Measurements to Examine Cardiac Morphology and Function in Pigs</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
</tr>
<tr>
<td>Normal</td>
<td>6</td>
</tr>
<tr>
<td>MI (3 Months)</td>
<td>6</td>
</tr>
</tbody>
</table>

Values are presented as mean±SEM; *p<0.05 vs. Normal; MI – Myocardial Infarction; WT – Wall Thickening; FS – Fractional Shortening; EF – Ejection Fraction.
MACO (MACO-negative) were significantly older females, were more likely to have anterior MI on the ECG on presentation, and lower LVEF on in-hospital echocardiogram within 72-hours post-MI. Of the 52 STEMI patients, 43 patients had echocardiography performed during hospitalisation with only one patient having a prior documented history of HF. Of these patients, eight had severely reduced LV systolic function and showed a significant (2.96-fold) increase of serum galectin-3 concentrations, compared to controls (p<0.001). Using the assessment of LVEF obtained from the ventriculogram at the time of revascularisation, STEMI patients with severely reduced LV systolic function had a 3.57-fold increase of serum galectin-3 levels (p<0.001), compared to a smaller 1.50-fold increase in STEMI patients without severely reduced LV systolic function (p<0.001). Comparison of serum galectin-3 levels between STEMI patients with severely reduced LV systolic function vs. STEMI patients without severely reduced LV systolic function (Figure 4A), showed a borderline significance (p=0.055) and will need to be validated in a larger sample size. The association of elevated galectin-3 levels in relation to poor outcomes is elucidated by the results of the primary composite endpoint MACO (Figure 4B). MACO-positive patients had a significantly greater fold-increase in serum galectin-3 concentration than MACO-negative patients (5.05±1.67 vs. 1.34±0.21; p<0.01). These findings indicate an association of elevated galectin-3 level with poor outcomes in STEMI patients, which may aid in identifying the subset of patients en route to the development of ischaemic cardiomyopathy as early targets for appropriate therapeutic interventions. Galectin-3 levels were not associated with elevated LVEDP on angiogram, elevated E/E’ ratio or presence of diastolic dysfunction.

**Figure 2** Comparison of left ventricular systolic function and serum levels of galectin-3 in normal and 90-days post-MI pigs. These pigs underwent coronary microembolisation procedure using polystyrene microsphere infusion for 5 minutes. LV systolic function was examined by transthoracic echocardiogram with a specialised large animal-specific ultrasound probe (panel A). The serum galectin-3 immunoassays were performed in our lab with a standard 96-well ELISA kit. Total serum concentrations were then quantified using pre-specified concentrations of recombinant galectin-3 to generate the standard curves (panel B). * p<0.05 compared to baseline measurements for both panels.

**Figure 3** Immuno-histological demonstration of post-MI myocardial galectin-3 expression. A, a representative microscopic image of pig myocardium showing galectin-3 immunohistochemical staining. Galectin-3 staining is localised primarily to the areas of cardiomyocyte damage. Intense galectin-3 staining was visualised inside the large vacuolated cells (arrows) that were previously characterised by us as tissue macrophages. B, a representative image of galectin-3 immunohistochemical staining of a control pig myocardium. There is no myocyte damage, which correlates with the lack of galectin-3 staining (original magnifications 200x).
dysfunction greater than stage 1 on echocardiogram, however were associated with high atrial volume index (Table 4).

**Discussion**

The increasing prevalence of ischemic cardiomyopathy represents a major health problem; thus finding possible new approaches to its early identification and treatment are of great significance. Although galectin-3 has developed rapidly from the bench to bedside as a biomarker, the dynamic of galectin-3 expression in relation to other mediators of cardiac remodelling required further study. In this study, we have examined that galectin-3 is not only a marker on itself but also shows a concerted relationship with other inflammatory and myocardial matricellular genes dynamically overexpressed in relation to acute MI. In patients with acute MI, serum galectin-3 overexpression is associated with major adverse cardiovascular outcomes.

Our largest-to-date and comprehensive temporal gene expression profile has provided important and previously

---

**Table 3** Demographic characteristics of all patients, and comparison between patients with MACO-positive* versus negative MACO-negative*

<table>
<thead>
<tr>
<th>Baseline Characteristics</th>
<th>All patients (N=52)</th>
<th>MACO-negative (n=43)</th>
<th>MACO-positive (n=9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, yrs</td>
<td>63.7 ± 11.7</td>
<td>61.7 ± 1.7</td>
<td>73.3 ± 3.4*</td>
</tr>
<tr>
<td>Male gender, %</td>
<td>59.6</td>
<td>65.1</td>
<td>33.3</td>
</tr>
<tr>
<td>Caucasian, %</td>
<td>96.2</td>
<td>97.7</td>
<td>88.9</td>
</tr>
<tr>
<td>Prior MI, %</td>
<td>13.7</td>
<td>11.9</td>
<td>22.2</td>
</tr>
<tr>
<td>ASA use, %</td>
<td>23.1</td>
<td>20.9</td>
<td>33.3</td>
</tr>
<tr>
<td>Statin use, %</td>
<td>28.8</td>
<td>32.6</td>
<td>11.1</td>
</tr>
<tr>
<td>Beta blocker use, %</td>
<td>25.0</td>
<td>23.3</td>
<td>33.3</td>
</tr>
<tr>
<td>ACEi use, %</td>
<td>23.1</td>
<td>20.9</td>
<td>33.3</td>
</tr>
<tr>
<td>Diuretic use, %</td>
<td>7.7</td>
<td>7.0</td>
<td>11.1</td>
</tr>
<tr>
<td>Peak troponin, ng/ml</td>
<td>81.51 ± 14.73</td>
<td>70.97 ± 14.54</td>
<td>131.89 ± 48.00</td>
</tr>
<tr>
<td>Anterior MI, %</td>
<td>32.7</td>
<td>25.6</td>
<td>66.7*</td>
</tr>
<tr>
<td>LVEDP, mmHg</td>
<td>21.6 ± 1.6</td>
<td>21.3 ± 1.7</td>
<td>24.2 ± 4.6</td>
</tr>
<tr>
<td>LVEF (Echo-based) after MI</td>
<td>47.6 ± 1.8</td>
<td>50.3 ± 1.8</td>
<td>37.8 ± 4.3*</td>
</tr>
<tr>
<td>Serum galectin-3, fold increase compared to controls</td>
<td>1.98 ± 0.38</td>
<td>1.34 ± 0.21</td>
<td>5.05 ± 1.67*</td>
</tr>
</tbody>
</table>

Results are expressed as percentage, or Mean ± SEM. *p<0.05 vs MACO-negative.

MACO: Major adverse cardiac outcomes. MACOs are defined as composite endpoint of all-cause mortality, recurrent MI, stroke, and severely reduced LVEF of ≤35% on ventriculogram. MI - myocardial infarction; ASA - aspirin; ACEi - angiotensin converting enzyme inhibitor; and LVEDP - left ventricular end diastolic pressure.

---

**Figure 4** Comparison of fold changes in serum galectin-3 level in patients with LVEF ≤35% and >35% on ventriculogram (Panel A) and in MACO – and MACO + patients (Panel B). The serum galectin-3 immunoassays were performed in our lab with a standard 96-well ELISA kit. The fold change in serum galectin-3 level is from its baseline, i.e. compared to healthy control. Data are expressed as Mean ± standard error of mean (SEM). *, p<0.05 compared to control group; #, p<0.05 compared to MACO- group in Panel B.
unknown expression dynamics of galectin-3. With a similar genomic strategy, we had previously identified galectin-3 as a novel mediator of HF and its downregulation following therapy with angiotensin receptor antagonists in a hypertensive rat model [4,21]. Galectin-3 was then found to be overexpressed in the myocardium of the rodents en route to the development of HF. Many other clinical studies, including the Framingham Heart Study, later expanded the utility of galectin-3 as a biomarker for cardiac remodelling, fibrosis, and early mortality due to HF exacerbation and recurrent hospitalisations [5,17,33,36–38]. Our pre-clinical studies in an angiotensin-II overexpression model have also shown galectin-3 as a possible early mediator of cardiac dysfunction and subsequent HF [4]. The current study expands our previous discovery to the next level as galectin-3 shows a robust and dynamic myocardial expression after acute MI.

It is noteworthy that gene-expressions are not always translated to post-transcriptional protein synthesis. However, our prior microarray study with the similar array platform allowed us to validate these genes by real-time PCR, Western blotting, immunohistochemistry and functional studies [4]. After identifying increased galectin-3 gene expression in the infarct region, we have validated these findings at tissue and serum levels using a translational porcine model of acute MI. More specifically, a porcine model of coronary micro-embolism shows acute myocardial injury followed by rapid LV remodelling and loss of cardiac function [25]. We decided to re-examine the LV function and serum galectin-3 levels in these pigs after three moths post-MI, a time-point that is often used in a clinical set up to discern treatment responsiveness.

Unlike other clinical biomarkers, it is known that galectin-3 has pro-fibrotic activity and can lead to loss of cardiac function [4]. Cardiac fibroblasts have abundant intracytoplasmic and perinuclear galectin-3 receptors. Intrapericardial infusion of galectin-3 leads to LV dysfunction and excess collagen I deposition [4]. Since the functional dynamics of galectin-3 were characterised in our prior studies, both in vitro and in vivo, it is important to recognise that sustained myocardial and peripheral galectin-3 increase in response to acute MI can be a culprit mechanism during the transition from compensated state to HF.

While the remote zone in an acute MI is not directly injured by the infarction, it is exposed to increased wall tension and abnormal shear forces following the infarction and, in mice, decompensates within weeks [14]. Unlike the dynamic changes noted in the infarct region, only a minimal increase of galectin-3 expression (maximum increase: 1.5-fold, two days post MI) was noted in the remote segments. There were multiple genes that showed increased expression in the infarct region or similarly in infarct and remote regions, but none were completely unique to the remote regions.

Taken together, this large, comprehensive microarray study and its translational validation have provided insights into several important aspects of post-infarct cardiac remodelling. Galectin-3 is highly overexpressed in the infarct regions after acute MI. The natriuretic peptide, a commonly used HF biomarker, also shows a similar dynamic expression but peaks at a much earlier time point (two days). Interestingly, galectin-3 gene expression dynamics closely follow the expression of other molecules responsible for myocardial remodelling. Furthermore, increased serum and myocardial galectin-3 protein levels were noted in a translational preclinical model of coronary microembolism-induced acute myocardial injury. Additionally, the association of serum galectin-3 levels with severely reduced LV function and poor cardiovascular outcomes has been validated in the clinical setting through our clinical study. The difference between this study and prior clinical studies is that, while the prognostic role of galectin-3 has been previously demonstrated in patients with ACS [7,8,9], our study is the first to-date to also demonstrate the association between galectin-3 levels and poor cardiovascular outcomes as early as in-hospital outcomes. This is important as translational studies on porcine models have demonstrated that severe LV dysfunction immediately following microsphere injection has persisted

### Table 4 Comparison of echocardiographic (< 72 h) and angiographic diastolic parameters in patients in relation to galectin-3 levels

<table>
<thead>
<tr>
<th>Early outcomes</th>
<th>(N)</th>
<th>Fold increase of galectin-3 from baseline (compared to controls)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LVEDP ≤ 20mmHg</td>
<td>(25)</td>
<td>1.44 ± 0.29</td>
</tr>
<tr>
<td>LVEDP &gt; 20mmHg</td>
<td>(10)</td>
<td>2.32 ± 0.83</td>
</tr>
<tr>
<td>Diastolic dysfunction ≤ stage I</td>
<td>(39)</td>
<td>1.57 ± 0.32</td>
</tr>
<tr>
<td>Diastolic dysfunction &gt; stage I</td>
<td>(5)</td>
<td>2.59 ± 1.49</td>
</tr>
<tr>
<td>Atrial volume index ≤ 35</td>
<td>(26)</td>
<td>1.06 ± 0.23</td>
</tr>
<tr>
<td>Atrial volume index &gt; 35</td>
<td>(5)</td>
<td>3.32 ± 1.14*</td>
</tr>
<tr>
<td>E/E’ ratio &lt; 15</td>
<td>(30)</td>
<td>1.56 ± 0.37</td>
</tr>
<tr>
<td>E/E’ ratio ≥ 15</td>
<td>(10)</td>
<td>2.22 ± 0.94</td>
</tr>
</tbody>
</table>

Results are expressed as Mean ± SEM. *p<0.05.

LVEDP - left ventricular end diastolic pressure; and E/E’ ratio - ratio of mitral peak velocity of early filling to early diastolic mitral annular velocity.
as long as three months [25]. The association between galactin-3 levels and early LV dysfunction, hours after STEMI, makes it a possible very-early biomarker predicting long-term ischaemic cardiomyopathy, though longitudinal prospective studies are indicated to support this concept.

Finally, this study has advanced our prior discoveries and helped bridge translation gaps on the role of galectin-3 expression en route to cardiac remodelling. The implications of these studies are: a) Galectin-3 is a novel marker and a likely mediator of post-infarct cardiac remodelling; b) Concerted expression of galectin-3 and other mediators at two weeks implicates one to two weeks post MI as a meaningful time-point to initiate or optimise medical therapy. Further studies are required to further examine the causative and possibly a mechanistic role of galectin-3 to mediate post-infarct cardiac remodelling and loss of cardiac function.

Competing Interests
None

Acknowledgements
Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR001412 to the University at Buffalo. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This study was supported by ZonMW grant (917.36.320) to Dr. WM Blanksteijn.

References


